Hualan Biological: Net profit of 940 million yuan in 2025, with several new products in clinical research stages.

On March 27, Hualan Biological announced its 2025 annual report, with operating revenue of 4.6 billion yuan, an increase of 4.9% year-on-year; net profit attributable to the parent company was 940 million yuan, a decrease of 13.6%; net profit attributable to the parent company after deducting non-recurring gains and losses was 937 million yuan, a decrease of 4.5%; net cash flow from operating activities was 878 million yuan, a decrease of 17.1%; EPS (fully diluted) was 0.5146 yuan.

In the fourth quarter, the company’s operating revenue was 1.22 billion yuan, an increase of 36.9% year-on-year; net profit attributable to the parent company was 156 million yuan, a decrease of 5.0%; net profit attributable to the parent company after deducting non-recurring gains and losses was 194 million yuan, an increase of 18.8%; EPS was 0.0854 yuan.

In the 2025 annual report, the company pointed out that its main business operations remained stable, with good performance in the research, production, and sales of blood products and vaccines. During the reporting period, the company achieved 1,669.49 tons of plasma collection in blood products, a year-on-year increase of 5.24%. Among them, the plasma stations under the listed company collected 1,015.02 tons of plasma, an increase of 11.81% compared to the previous year; while the plasma stations under the Chongqing company collected 654.47 tons, a decrease of 3.55% compared to the previous year. In addition, the vaccine products of the company’s holding subsidiary, Hualan Biological Vaccine Co., Ltd., such as the influenza virus split vaccine, continued to maintain a leading position in the market.

The company has also made significant progress in the research and development of innovative drugs and biosimilars, with multiple new products in the clinical research stage. The report mentioned that Bevacizumab was officially produced and sold in 2025, and other drugs such as Rituximab and Dexamethasone are also accelerating their listing applications. The company will continue to strengthen R&D investment in the future to promote the development and market promotion of new products, enhancing the company’s market competitiveness and long-term development momentum.

(Hualan Biological Announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare